Targeted Methylation Probe Panel for Cost-Effective Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DNA methylation profiling methods, such as whole genome bisulfite sequencing (WGBS), are not cost-effective for cancer diagnosis due to low differentially methylated regions and high sequencing costs, and struggle with small control groups and methylation dependencies, limiting accurate disease detection.
Innovation Solution
A targeted methylation probe panel is developed for hybridization capture, comprising oligonucleotide probes complementary to cancer-specific genomic regions with differentially methylated CpG sites, allowing for enriched sequencing of relevant genomic regions using cell-free DNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If whole genome bisulfite sequencing (WGBS) is used for DNA methylation profiling, then comprehensive methylation coverage is achieved, but sequencing costs increase and diagnostic accuracy decreases due to low differentially methylated regions
Solution Approach 1:
The patent extracts and focuses sequencing efforts on specific differentially methylated regions (DMRs) rather than sequencing the entire genome. By designing probes that target only these relevant genomic regions, the method concentrates resources on areas most likely to provide diagnostic information, thereby reducing overall sequencing costs while maintaining or improving detection accuracy for cancer-related methylation changes
Solution Approach 2:
The patent applies local quality by creating probes with specific properties tailored to different genomic regions. The probes are designed with optimal lengths, GC contents, and melting temperatures suited for hybridization to specific DMRs. This localized optimization of probe characteristics ensures high-quality data acquisition from targeted regions without the resource expenditure required for whole-genome sequencing
2Measurement precision
If WGBS is used to achieve deep sequencing, then only a small set of genomic regions (0.1% of genome) can be sequenced at current costs, but this limits the ability to identify all differentially methylated regions
Solution Approach 1:
The patent segments the genome into specific differentially methylated regions that are most relevant for cancer diagnosis. Rather than attempting to sequence the entire genome or relying on random sampling, the method divides the genomic landscape into discrete, probe-targetable segments (DMRs) and applies deep sequencing selectively to these segments. This segmentation allows both high sequencing depth and broader effective coverage of diagnostically relevant regions
Solution Approach 2:
The patent performs preliminary identification of differentially methylated regions through bioinformatic analysis and experimental validation before designing the targeted sequencing panel. This preliminary action ensures that the subsequent deep sequencing effort is focused on regions that have been pre-validated as differentially methylated, maximizing the utility of sequencing depth while avoiding waste on non-informative regions
3Device complexity
If small control groups are used in methylation profiling, then study design is simplified, but determination of differentially methylated regions loses confidence
Solution Approach 1:
The patent introduces a panel of pre-validated differentially methylated regions as an intermediary between the small control group and the diagnostic application. These DMRs serve as stable, reproducible markers that have been established through prior research and validation. By focusing on these intermediary markers rather than attempting to discover new ones in each small study, the method maintains high confidence in results even when control group sizes are limited
4Measurement precision
If methylation dependencies between adjacent CpG sites are accounted for, then more accurate methylation patterns are captured, but analysis complexity increases
Solution Approach 1:
The patent merges adjacent CpG sites into differentially methylated regions (DMRs) that are analyzed as unified units rather than isolated sites. By combining information from multiple adjacent CpG sites into single DMR metrics (such as average methylation level or presence/absence of hypermethylation), the method captures the interdependencies between adjacent sites while simplifying the overall analysis framework. This merging approach maintains the biological reality of methylation clusters without requiring complex statistical models for each individual site
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables cost-effective, non-invasive early cancer detection by providing accurate cancer-specific methylation pattern analysis, improving sequencing depth and diagnostic accuracy.
Implementation Method 1
A targeted methylation probe panel is developed for hybridization capture, comprising oligonucleotide probes complementary to cancer-specific genomic regions with differentially methylated CpG sites
Data Source
AI summary
The present description provides a cancer assay panel for targeted detection of cancer-specific methylation patterns. Further provided herein are methods of designing, making, and using the cancer assay panel for the diagnosis of cancer.